Brief: Ideaya Biosciences Inc - Servier And Ideaya Enter Exclusive License For Darovasertib Outside Us
02/09/2025 13:23
IDEAYA Biosciences Inc IDYA.O: IDEAYA BIOSCIENCES INC - SERVIER AND IDEAYA ENTER EXCLUSIVE LICENSE FOR DAROVASERTIB OUTSIDE US IDEAYA BIOSCIENCES INC - TO RECEIVE $210 MILLION UPFRONT, UP TO $320 MILLION IN MILESTONES IDEAYA BIOSCIENCES INC - CO AND SERVIER TO LAUNCH GLOBAL PHASE 3 TRIAL FOR DAROVASERTIB IN 2026 Source text: ID:nPn8YW75Ma Further company coverage: IDYA.O
Recent news on IDEAYA Biosciences
See all newsBrief: Ideaya Biosciences And Servier Announce Data From Three Clinical Trials At Esmo 2026 Supporting The Potential Of Darovasertib To Become A Foundational New Therapy For Patients Across The Treatment Journey Of Uveal Melanoma
Brief: Ideaya Biosciences Announces The Promotion Of Dr. Michael White To President, Research And Development
Brief: Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ideaya Biosciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj